JP2022521956A5 - - Google Patents

Info

Publication number
JP2022521956A5
JP2022521956A5 JP2021549630A JP2021549630A JP2022521956A5 JP 2022521956 A5 JP2022521956 A5 JP 2022521956A5 JP 2021549630 A JP2021549630 A JP 2021549630A JP 2021549630 A JP2021549630 A JP 2021549630A JP 2022521956 A5 JP2022521956 A5 JP 2022521956A5
Authority
JP
Japan
Prior art keywords
seq
amino acid
acid sequence
heavy chain
light chain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021549630A
Other languages
English (en)
Japanese (ja)
Other versions
JP7554759B2 (ja
JP2022521956A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/019763 external-priority patent/WO2020176549A1/en
Publication of JP2022521956A publication Critical patent/JP2022521956A/ja
Publication of JP2022521956A5 publication Critical patent/JP2022521956A5/ja
Application granted granted Critical
Publication of JP7554759B2 publication Critical patent/JP7554759B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021549630A 2019-02-26 2020-02-25 Ｂｃｍａに結合する抗原結合性タンパク質 Active JP7554759B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962810771P 2019-02-26 2019-02-26
US62/810,771 2019-02-26
US201962811431P 2019-02-27 2019-02-27
US62/811,431 2019-02-27
PCT/US2020/019763 WO2020176549A1 (en) 2019-02-26 2020-02-25 Antigen binding proteins that bind bcma

Publications (3)

Publication Number Publication Date
JP2022521956A JP2022521956A (ja) 2022-04-13
JP2022521956A5 true JP2022521956A5 (https=) 2023-01-26
JP7554759B2 JP7554759B2 (ja) 2024-09-20

Family

ID=72238662

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021549630A Active JP7554759B2 (ja) 2019-02-26 2020-02-25 Ｂｃｍａに結合する抗原結合性タンパク質

Country Status (12)

Country Link
US (1) US20210388097A1 (https=)
EP (1) EP3930852A4 (https=)
JP (1) JP7554759B2 (https=)
KR (1) KR20210133261A (https=)
CN (1) CN113874082B (https=)
AU (1) AU2020228367A1 (https=)
BR (1) BR112021016791A2 (https=)
CA (1) CA3130765A1 (https=)
IL (1) IL285813A (https=)
MX (1) MX2021010281A (https=)
SG (1) SG11202109163YA (https=)
WO (1) WO2020176549A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022546577A (ja) * 2019-09-05 2022-11-04 ソレント・セラピューティクス・インコーポレイテッド Ｂｃｍａと結合する二量体抗原受容体（ｄａｒ）
TWI905354B (zh) 2020-12-31 2025-11-21 法商英耐特醫藥公司 結合至NKp46及CD123之多功能自然殺手 (NK) 細胞接合體
US20240181073A1 (en) 2021-03-03 2024-06-06 Sorrento Therapeutics, Inc. Antibody-Drug Conjugates Comprising an Anti-BCMA Antibody
KR20250017240A (ko) 2022-05-27 2025-02-04 사노피 FC-조작을 갖는 NKp46 및 BCMA 변이체에 결합하는 자연 살해(NK) 세포 관여자
EP4532543A1 (en) * 2022-05-27 2025-04-09 Sanofi Anti-bcma antibodies
CN119841951B (zh) * 2024-12-25 2025-10-14 厦门大学附属第一医院(厦门市第一医院、厦门市红十字会医院、厦门市糖尿病研究所) 一种抗bcma抗体或其抗原结合片段及其制备方法和应用

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6342220B1 (en) * 1997-08-25 2002-01-29 Genentech, Inc. Agonist antibodies
GB9908533D0 (en) * 1999-04-14 1999-06-09 Novartis Ag Organic compounds
US7214786B2 (en) * 2000-12-14 2007-05-08 Kovalic David K Nucleic acid molecules and other molecules associated with plants and uses thereof for plant improvement
CN1838968A (zh) * 2003-08-08 2006-09-27 艾伯吉尼斯公司 针对甲状旁腺激素(pth)之抗体和其用途
PL2188313T3 (pl) * 2007-08-21 2018-04-30 Amgen, Inc. Białka wiążące ludzki antygen c-fms
CN104781280A (zh) * 2012-11-13 2015-07-15 瑞泽恩制药公司 抗前动力蛋白受体(prokr)抗体及其使用
TW201425336A (zh) * 2012-12-07 2014-07-01 Amgen Inc Ｂｃｍａ抗原結合蛋白質
KR20180016972A (ko) * 2015-02-22 2018-02-20 소렌토 쎄라퓨틱스, 인코포레이티드 Cd137에 결합하는 항체 치료제
TWI703159B (zh) * 2015-04-13 2020-09-01 美商輝瑞股份有限公司 Bcma特異性治療性抗體及其用途
MX2018002043A (es) * 2015-08-17 2018-07-06 Janssen Pharmaceutica Nv ANTICUERPOS ANTI-BCMA, MOLí‰CULAS DE UNIí“N A ANTíGENOS BIESPECíFICAS QUE SE UNEN A BCMA Y CD3, Y USOS DE ESTOS.
CN108778329B (zh) * 2016-02-17 2022-09-16 西雅图基因公司 Bcma抗体和其用以治疗癌症和免疫病症的用途
MA51447A (fr) * 2017-08-01 2020-06-10 Medimmune Llc Conjugué anticorps monoclonal-médicament dirigé contre bcma
US20200224160A1 (en) * 2018-02-27 2020-07-16 Sorrento Therapeutics, Inc. Process for dna integration using rna-guided endonucleases
CN109265550B (zh) * 2018-09-25 2020-09-15 华东师范大学 Bcma抗体、嵌合抗原受体和药物
JP2022546577A (ja) * 2019-09-05 2022-11-04 ソレント・セラピューティクス・インコーポレイテッド Ｂｃｍａと結合する二量体抗原受容体（ｄａｒ）

Similar Documents

Publication Publication Date Title
JP2022521956A5 (https=)
JP7273101B2 (ja) Ｃｄ３８に結合する抗体治療剤
US11524991B2 (en) PD-1 targeted heterodimeric fusion proteins containing IL-15/IL-15Ra Fc-fusion proteins and PD-1 antigen binding domains and uses thereof
US12448423B2 (en) Targeted heterodimeric Fc fusion proteins containing NKG2D antigen binding domains
JP7250736B2 (ja) Ｂｃｍａおよびｃｄ３に対する結合分子
CN110799539B (zh) 抗4-1bb抗体及其制备和使用方法
AU2016339832B2 (en) Antibody agents specific for human CD19 and uses thereof
JP7397882B2 (ja) 二重特異性抗体及びその調製方法、使用
JP2022527084A5 (https=)
JP2016511277A (ja) Ｂｃｍａおよびｃｄ３に対する結合分子
JP2016513467A5 (https=)
RU2011145428A (ru) АНТИТЕЛА ПРОТИВ TNF-α И ИХ ПРИМЕНЕНИЯ
JP2017537082A5 (https=)
US20250206820A1 (en) Ilt3 and cd3 binding agents and methods of use thereof
EP2751139A1 (en) Caninised tumour necrosis factor antibodies and methods of using the same
JP2024516098A5 (https=)
CN114025797A (zh) 抗Gal9免疫抑制性结合分子
JP7574692B2 (ja) 二重特異性抗体
KR20250059424A (ko) Pd-1 작용제 항체
RU2021128015A (ru) Антигенсвязывающие белки, которые связываются с bcma
US20260008861A9 (en) Anti-4-1bb antibodies and methods of making and using thereof
RU2841957C1 (ru) Сконструированные антитела против il-2
EP4603509A1 (en) Multifunctional recombinant antibody, and preparation method and use therefor
JP2025541365A (ja) 多価造血細胞係合因子または活性化因子
WO2022003693A1 (en) Anti-tumor necrosis factor receptor (tnfr2) antibodies and uses thereof